Zai Lab (ZLAB) Remains a Buy Amid Strong Commercial and Pipeline Momentum

ZLAB -2.71%

Zai Lab Limited (NASDAQ:ZLAB) is one of the 12 oversold global stocks to invest in.

As of November 27, Zai Lab Limited (NASDAQ:ZLAB) is a consensus Buy with over 90% analysts covering it having a Buy, Strong Buy, or equivalent rating. With a consensus 1-year average price target of $49.49, the stock has a 147.82% upside potential.

On November 7, 2025, Zai Lab Limited (NASDAQ:ZLAB) saw UBS reiterate a “Buy” rating on the company’s Hong Kong-listed shares with a HK$33.50 price target.

Just a day earlier, Zai Lab Limited (NASDAQ:ZLAB) announced its Q3 2025 results, reflecting continued momentum across its commercial and pipeline programs. The company’s product revenue grew 13.0% YoY to $115.4 million. Revenue growth was driven by NUZYRA and XACDURO, partially offset by softer ZEJULA sales. With its sales reaching $27.7 million, VYVGART experienced extended therapy duration and increased market share despite a voluntary $2.4 million price adjustment for Hytrulo. While adjusted loss from operations saw improvement to $28.0 million, net loss narrowed to $36.0 million, or $0.03 per share.

Recapping the developments that took place during the quarter, management cited Zocilurtatug Pelitecan (zoci), which advanced into pivotal studies in second-line extensive-stage small cell lung cancer. Furthermore, they highlighted povetacicept’s progression in IgA nephropathy trials. Management also expressed optimism about VYVGART’s increasing adoption in generalized myasthenia gravis. The quarter also saw KarXT preparation in schizophrenia progressing alongside favorable new national treatment guidelines. With robust expansion of its global pipeline, Zai Lab Limited (NASDAQ:ZLAB) looked ahead with confidence, reaffirming full-year 2025 revenue guidance of at least $460 million, driven by disciplined execution and growing commercial presence in China.

Zai Lab Limited (NASDAQ:ZLAB), a research-based, commercial-stage biopharmaceutical company, focuses on innovative therapies for oncology, immunology, neuroscience, and infectious diseases.

While we acknowledge the potential of ZLAB as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 12 Best Commodity Stocks to Buy Right Now and 10 Best Crypto-Related Stocks to Invest In.

Disclosure: None.